Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “DERMATOSES”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 433 records · Page 24Linked to original sources
PubMed1977

Common canine dermatoses.

Refractory canine skin disorders from a large percentage of the cases referred to the Department of Medicine, Faculty of Veterinary Science, University of Pretoria. Included in these conditions are allergic skin diseases, primary pyoderma, generalised pustular demodicosis, endocrine alopecia, dermatomycosis, seborrhoea, acral pruritic nodule and nasal solar dermatitis. These conditions are discussed with emphasis on aetiology, pathogenesis, diagnosis and treatment. Thirteen colour plates illustrate the classical appearance of the dermatoses described.

Animals↗
PubMed1982

Colloid bodies in dermatoses other than lichen planus.

In a previous study on lichen planus the morphology and significance of the colloid bodies were discussed (13). In the present study a description is given of 30 dermatoses with colloid bodies, observed among unselected patients. The colloid bodies develop as a result of damage to the epithelium caused by circulatory disorders with subsequent hypo- or anoxia. Lichenoid cell infiltration into the connective tissue--nearly always present--aggravates the process. Dyskeratosis, pyknosis and fibrinoid necrosis of the damaged cells occur and the nuclei disintegrate. The resultant colloid bodies may coalesce or scatter or be expelled from the epithelium according to the principles of apoptosis (6, 7). Besides circulatory disorders, purely local damage and pathological processes involving the tissues should be regarded as important factors. Although the colloid bodies are characteristic for various skin diseases, they do not have an absolutely clear diagnostic significance. In doubtful cases their presence may nevertheless be considered a valuable contribution and supplement to the diagnosis.

Amyloid↗
PubMed1984

Expression of HLA-DR (Ia like) antigen on epidermal keratinocytes in human dermatoses.

Ia antigen (HLA-DR in man) has been demonstrated in keratinocytes in graft versus host disease. This study investigates the occurrence of HLA-DR in keratinocytes in the following dermatoses: eczematous dermatitis, discoid lupus erythematosus, with immunoglobulin and non-exposed skin from cases of systemic lupus erythematosus with immunoglobulin deposits, lichen planus, lichen simplex, bullous pemphigoid, pemphigus vulgaris, 'toxic erthema', tuberculid and chillblain. Keratinocyte staining was found in a variety of conditions. The unifying features of the instances of its occurrence was lymphoid infiltration and usually some focal evidence of keratinocyte damage. Thus in eczema the staining was mid-epidermal, while in discoid lupus erythematosus and lichen planus it was basal. HLA-DR staining was absent in bullous pemphigoid and pemphigus vulgaris, which is consistent with the hypothesis that in these conditions the damage is mediated by autoantibodies and complement in the absence of cellular immune attack.

HLA-DR Antigens↗
PubMed1983

[Therapy of erythrosquamous dermatoses. Betamethasone dipropionate plus salicylic acid in comparison with betamethasone dipropionate solution].

Efficacy and tolerance of an alcoholic solution containing 0.64 mg betamethasone-dipropionate plus 20 mg salicylic acid (Diprosalic Solution) were compared with an alcoholic solution containing 0,64 mg betamethasone-dipropionate in a 3 week double blind study in 100 patients with psoriasis and other steroid-responsive dermatoses of dry nature, comprising scalp and other hairy and non-hairy areas of the body. This double blind study was followed by a 3 week open study in another 100 patients with similar diagnosis, using Diprosalic Solution only. Although the therapeutic results of the double blind study showed no significant differences between both treatment groups, distinct advantages of the drug containing salicylic acid could be clearly demonstrated, such as: 1. More rapid onset of action, 2. rapid clearing of scaling, pruritus and inflammation, 3. these advantages are in compliance with the fact that topically applied salicylic acid softens keratin, loosens cornified epithelium and desquamates the epidermis, making the underlying layers more accessible to the antiinflammatory steroid.

Administration, Topical↗
PubMed1984

[Work in a humid environment as a conditioning factor in the genesis of occupation-induced dermatoses].

In a prospective study undertaken from 1980-1983 the risk of developing occupational eczemas among apprentices usually working in a wet environment was analysed. Investigations involving 305 volunteers from technical colleges revealed a marked increase of dermatoses in subjects occupationally exposed to wet conditions. The influence of water and detergents on the barrier function of the horny layer of the epidermis is discussed.

Adolescent↗
PubMed1983

[Dermatoses characteristic in particular occupations. I. Various branches of industry].

Dermatoses characteristic for several branches of industry: metal, electrotechnical, photochemical and pharmaceutical and for laminators and galvanizers are discussed. The periods are given after which skin changes appear, their primary localisation and the allergens specific for the particular occupations. In photo-chemical industry workers, beside dermatitis. lichen planus was also noted.

Dermatitis, Contact↗
PubMed1981

[Problems in the treatment and after care of chronic dermatoses. A clinical study on hametum ointment].

Two groups of patients with endogenous eczema (n = 36) and toxic degenerative eczema (n = 80) were treated with Hametum Salbe and a control preparation. The present results indicate that Hametum Salbe is superior in effectiveness in treatment of atopic dermatitis compared to the control preparation. There was no difference in therapeutical effectiveness in the treatment of primary irritant contact dermatitis. For treatment and interval therapy as well as for long-term treatment of chronic dermatoses Hametum Salbe is a valuable dermatological preparation which can be used without any risk in long-term therapy.

Adolescent↗
PubMed1983

An overview of international clinical trials with halometasone ointment in chronic eczematous dermatoses.

Four international, multicentre, comparative clinical trials were carried out by twenty-two dermatologists in 569 patients with non-infected chronic eczematous dermatoses in Austria, Germany, Spain, Switzerland and Yugoslavia. In these clinical trials halometasone ointment exhibited a very satisfactory therapeutic effect in all the five types of non-infected chronic eczematous dermatitis, namely chronic contact dermatitis, atopic dermatitis, lichen simplex chronicus, seborrhoeic dermatitis and nummular dermatitis. It yielded an overall success rate ('good' to 'very good' results) of 85% as against 71% obtained with the comparative preparations. With regard to therapeutic effect, halometasone ointment proved significantly superior (p = 0.0001) to Ultralan ointment but it was less effective than Dermovate ointment (p = 0.052). It yielded overall success rates higher than those obtained with Diproderm (84.6% versus 74.4%) and Synalar (88.5% versus 72%) ointments. Halometasone ointment was well tolerated and neither skin atrophy nor any systemic effect due to the transcutaneous systemic absorption of the corticoid was observed.

Administration, Topical↗
PubMed1983

Evaluation of halometasone ointment in the treatment of paediatric patients with chronic eczematous dermatoses.

Fifty children suffering from non-infected chronic eczematous dermatoses were treated with an ointment containing 0.05% halometasone, a new high potency trihalogenated synthetic corticosteroid. Halometasone ointment does not contain parabens or perfumes. The trial population consisted of patients (under 1 to 16 years old) with non-infected chronic nummular dermatitis, seborrhoeic dermatitis, atopic dermatitis and contact dermatitis. Halometasone ointment yielded very satisfactory therapeutic results and exhibited an excellent tolerability. It produced 'good' or 'very good' results in 82% of the patients and gave an overall cure rate of 76%. The number of patients obtaining an early cure, i.e. in less than 30 days, was thirty-six (72%). An early onset of therapeutic effect, i.e. within 6 days of starting the treatment, was reported in 77.1% of the patients. All the children (including eighteen infants) tolerated halometasone ointment well and no adverse effects, either due to local skin intolerability or the transcutaneous systemic absorption of the corticoid, were observed in this trial, nor were any instances of skin atrophy reported. Cosmetic acceptability and ease of application were considered 'good' in forty-nine (98%) patients.

Administration, Topical↗
PubMed1983

Evaluation of halometasone cream in the treatment of paediatric patients with acute eczematous dermatoses.

Sixty children under 10 years of age (including 18 under 3 years) suffering from non-infected acute eczematous dermatoses were treated with 0.05% halometasone cream containing a new high-potency trihalogenated synthetic dermatocorticosteroid. The trial population consisted of patients with acute atopic dermatitis, seborrhoeic dermatitis, nummular dermatitis and contact dermatitis. Halometasone cream yielded very satisfactory results and showed excellent tolerability. It produced 'good' or 'very good' results in 90% of the cases and gave an overall cure rate of 74.3%. The number of patients obtaining an early cure, i.e. in less than 20 days, was thirty-seven (62%). The onset of action was reported in 78.3% of the patients within 3 days of starting the treatment. All patients tolerated the treatment well and no adverse effects, either due to the topical application or the transcutaneous systemic absorption of the corticoid, were reported.

Acute Disease↗
PubMed1984

Studies on the efficacy and adrenal effects of Diprolene ointment 0.05 percent and Dermovate ointment 0.05 percent in patients with psoriasis or other resistant dermatoses.

The efficacy of Diprolene ointment 0.05 percent (betamethasone dipropionate in a glycol formulation) and Dermovate ointment 0.05 percent (clobetasone propionate) and their effects on adrenal function were evaluated in two double-blind, parallel group studies. A fixed dose of 7 gm of ointment a day was applied topically for fourteen days (Study 1) or twenty-one days (Study 2) to the skin of patients with psoriasis or other resistant dermatoses. To evaluate the adrenal effect of the treatments, plasma cortisol levels were determined for twenty of the sixty-one patients in Study 1 and for all of the twenty patients in Study 2. Efficacy and adverse experience data were evaluated for all patients. At the initial visit and at weekly follow-up visits, the selected lesions were graded for the severity of the signs and symptoms of disease. Most of the patients in these studies experienced a complete clearing of all the signs and symptoms of their disease by the end of the treatment with either Diprolene or Dermovate. The two treatments were equally effective. No adverse experiences were seen in the Diprolene group, but one patient with psoriasis in the Dermovate group had an exacerbation of the disease and the treatment was discontinued. In Study 1, reduction in plasma cortisol levels during treatment was observed in both groups, but to a distinctly lesser degree in the Diprolene than in the Dermovate group; levels below the normal range (184 to 767 nmol/l) were observed in one patient in the Diprolene group and in four patients in the Dermovate group.(ABSTRACT TRUNCATED AT 250 WORDS)

Adult↗
PubMed1980

Nonsteroidal topical treatment of inflammatory dermatoses.

Reports of local and systemic complications from topically applied corticosteroids used in the treatment of inflammatory dermatoses warrant a re-examination of other methods of therapy. The specific measures suggested in this paper for treating seborrheic dermatitis, psoriasis, and atopic dermatitis may also be applied to eczematous eruptions that are in similar stages of development.

Administration, Topical↗
PubMed1983

Clinical studies on the effectiveness of Wratizolin in the treatment of some dermatoses.

Clinical studies on therapeutic effectiveness of ITCL applied as 2-3% ointment, 2% cream and 2-3% lotion were carried out. The study material included 96 patients at the age of 9-80. Of this group, 19 patients were with herpes zoster, 16 with herpes simplex, 29 with eczema complicated by secondary bacterial infection, 30 with palm and foot pustulosis, 1 patient with actinic cheilitis and 1 with varicella. The results obtained have revealed that the preparation is particularly effective in the treatment of dermatoses induced by herpes zoster and herpes simplex virus.

Administration, Topical↗
PubMed1983

Betamethasone dipropionate and salicylic acid lotion for nonscalp dermatoses.

A multicentric open study was conducted to evaluate the efficacy and safety of betamethasone dipropionate and salicylic acid lotion in 86 patients with psoriasis or other steroid-responsive dermatoses of nonscalp body areas. Medication was applied to affected areas for 14 to 31 days. Patients were evaluated weekly. Within 14 to 21 days of therapy, there were favorable results in 68/86 (79%) patients. A complete clearing or marked improvement of signs and symptoms was achieved in 78/86 (91%) patients; improvement occurred in 7/86 (8%). Treatment failed in one (1%) patient. Three transient adverse reactions were reported.

Administration, Topical↗
PubMed1980

Treatment of infected dermatoses: a randomized, double-blind clinical trial in general practice.

A double-blind, randomized trial was carried out in 52 patients with infected dermatoses to compare the efficacy and tolerance of two topical antibiotic/steroid combinations in cream formulations, one containing triamcinolone acetonide, neomycin sulphate and undecenoic acid ('Silderm') and the other triamcinolone acetonide, neomycin sulphate, nystatin and gramicidin. Patients applied the cream 3-times daily for 7 days. Assessments carried out before and after treatment showed that the 'Silderm' formulation was the more effective of the two preparations in reducing the extent of lesion, cosmetic disfigurement and irritation, and patients reported a greater improvement in their condition than did those on the other cream. No side-effects were reported in either treatment group.

Administration, Topical↗
PubMed1982

Evaluation of a new halcinonide formulation in the treatment of common dermatoses.

An open evaluation of halcinonide 0.1 percent in a hydrophilic vanishing cream base was conducted in one hundred patients with common steroid-responsive dermatoses, including eczema, contact dermatitis, atopic dermatitis stasis dermatitis, and neurodermatitis. Patients applied the cream two or three times a day for two weeks (or less if the clinical response warranted earlier discontinuation). Follow-up assessments were made on days 4, 7, and 14 of the study. Ninety-eight percent of the patients showed some degree of improvement, and eighty-five percent had complete clearing or marked improvement. One patient had no response and one worsened. Seventy-seven percent of the patients who responded achieved their maximum response within the first week of treatment. One case of urticaria was the only side effect noted in this series. Ninety-six percent of the patients rated their acceptance of the new formulation as excellent or good.

Adolescent↗